Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
about
A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction.Buprenorphine for opioid dependenceClinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Drug treatment as HIV prevention: a research updateDrug treatment as HIV prevention: expanding treatment options.Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058Misuse of and dependence on opioids: study of chronic pain patients.Treating opioid addiction with buprenorphine-naloxone in community-based primary care settingsThe adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clustersIllicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.Prescription opioid use and misuse: piloting an educational strategy for rural primary care physicians.Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.Clinician beliefs and attitudes about buprenorphine/naloxone diversionThe Use of Neuromodulation in the Treatment of Cocaine Dependence.Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies.Buprenorphine implants in medical treatment of opioid addiction.Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening.Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting.Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
P2860
Q34098392-D98B6BCF-EE3E-4C0A-96BF-7E0B9D0367D6Q34119459-D273AB1C-4016-41CD-A78D-F37DFD4CE5F5Q34787766-576DA07C-7DAB-47C9-BE6C-1D39C2C8559FQ35109559-4E4EF864-A197-45AE-A7D1-AA415DE1AA42Q35160035-4F993DD7-7578-4B10-9B5A-C61EB9D17546Q35163392-264E9535-E675-47D6-9B0D-1B06F778E280Q35163396-041DE2AC-B1B2-4541-AEBD-E8A641675C57Q35244943-0089D976-B0A4-45C7-B5FC-F29B35D9AF27Q35613256-7040AA5E-D36F-4BAE-9F76-D63DBB900F6AQ35721931-74A5E035-6508-49E3-9ECD-733A0AE320CAQ35792939-042A9C08-CCF9-4ACC-92F8-76FFC25B2D9BQ35800468-FC1B1BD8-180C-4C04-BFC3-05713CFFB4C9Q35886447-C73022A5-B5A9-4CB2-9F15-701475387A1DQ36431907-4B543EB2-30C7-4B74-A341-C2D3645D9B4EQ36706966-BABEC367-E06D-409C-84B1-80568357448AQ36711790-51A62454-4A8E-451D-931F-45FAD052D136Q37241381-86D4FB3D-C8FD-4733-9FE9-C83FF065B0B6Q37639311-F978CE03-2965-48C7-BCCE-B40585129A49Q38244651-B1520909-BE3C-4671-93FD-AED9683EA6ABQ38750450-9F878EE3-C9D2-433F-8398-C23E0529E718Q43218767-BC68D8FC-BAB9-4917-9A23-1173F0BDCE1CQ44336891-CCB589A3-333D-4059-9365-2F78EB21D56AQ44351501-208E57EB-54A6-4FE6-B7FC-E6D1B9B3D1EA
P2860
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Safety and health policy consi ...... eatment for opiate dependence.
@ast
Safety and health policy consi ...... eatment for opiate dependence.
@en
type
label
Safety and health policy consi ...... eatment for opiate dependence.
@ast
Safety and health policy consi ...... eatment for opiate dependence.
@en
prefLabel
Safety and health policy consi ...... eatment for opiate dependence.
@ast
Safety and health policy consi ...... eatment for opiate dependence.
@en
P2093
P1476
Safety and health policy consi ...... eatment for opiate dependence.
@en
P2093
Deborah B Leiderman
Paul J Fudala
Susan Herbert
T Peter Bridge
P304
P356
10.1016/S0376-8716(03)00061-9
P433
P577
2003-05-01T00:00:00Z